As oil prices rise with increasing global uncertainty, this pharmaceutical stock emerges as a possible safe haven for income ...

Pfizer's phase II study evaluating CDK4 inhibitor, atirmociclib, in 2L metastatic breast cancer meets primary endpoint. Supports oncology pipeline progress.

Pfizer Inc. Q4 shows post-COVID growth, Seagen-fueled oncology gains, and obesity upside. Click for this updated look at PFE at its earnings and acquisition.

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

Pfizer (PFE) stock is in focus as a mid-stage trial for the company's investigational breast cancer therapy, atirmociclib succeeds. Read more here.

Is PFE a good stock to buy now? We came across a bullish thesis on Pfizer Inc. on Investomine’s Substack. In this article, we will summarize the bulls’ thesis on PFE.

Pfizer Inc. (NYSE:PFE) is one of Goldman Sachs top healthcare stocks. On March 9, analysts at BMO reiterated an Outperform rating on Pfizer Inc. (NYSE:PFE) and a $30 price target. The bullish stance ...

Qure shares finished the regular trading week down only 9% despite the FDA’s hard-line stance and public criticism against the company’s Huntington’s disease (HD) gene therapy candidate AMT-130.

It has been about a month since the last earnings report for Pfizer (PFE). Shares have lost about 0.6% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the ...

Deep-pocketed investors have adopted a bearish approach towards Pfizer (NYSE:PFE), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

One of the market stories dominating the headlines over the past year has been prediction markets/betting apps. I'm sure you've seen ads for Kalshi, Polymarket, and DraftKings. The first time I heard ...